Lilly has also signaled that seven more Phase 3 trials for retatrutide are expected to conclude in 2026, making it a pivotal ...

Eli Lilly has outperformed the broader market over the past year, and analysts remain highly bullish about the stock’s ...

While riding high on the popularity of its weight loss drug Zepbound, the company is quietly building a presence in a cutting ...

Eli Lilly and Company (NYSE:LLY) is one of the best long term low volatility stocks to invest in. Eli Lilly and Company (NYSE ...

Eli Lilly is scheduled to report its fourth-quarter results before the market opens Wednesday. Here is what you need to know. PROFIT: Analysts polled by FactSet expect the company to post net income ...

Eli Lilly and Co. has announced $50 billion in U.S. expansion commitments since 2020, including numerous manufacturing plants ...

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of ...

How the Lehigh Valley beat hundreds of competitors to land Eli Lilly’s $3.5 billion pharmaceutical plant ...

The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key ...

Novo Nordisk's stock plummets over 13% after the company warns of potential sales and profit declines in 2026, facing increasing competition in the weight-loss market, particularly from Eli Lilly's ...

Novo, which makes Ozempic and Wegovy, said it expected sales to fall by between 5% and 13% this year compared with growth of ...

COPENHAGEN, Feb 3 () - Wegovy maker Novo Nordisk warned on Tuesday that profits and sales could drop as much as 13% this year ...